What is the share price of Natco Pharma Ltd (NATCOPHARM) today?
The share price of NATCOPHARM as on 5th February 2026 is ₹830.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Natco Pharma Ltd (NATCOPHARM) share?
The past returns of Natco Pharma Ltd (NATCOPHARM) share are- Past 1 week: 2.89%
- Past 1 month: -6.00%
- Past 3 months: 2.59%
- Past 6 months: -10.01%
- Past 1 year: -31.92%
- Past 3 years: 59.66%
- Past 5 years: -6.46%
What are the peers or stocks similar to Natco Pharma Ltd (NATCOPHARM)?
The peers or stocks similar to Natco Pharma Ltd (NATCOPHARM) include:What is the dividend yield % of Natco Pharma Ltd (NATCOPHARM) share?
The current dividend yield of Natco Pharma Ltd (NATCOPHARM) is 0.71.What is the market cap of Natco Pharma Ltd (NATCOPHARM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Natco Pharma Ltd (NATCOPHARM) is ₹15064.93 Cr as of 5th February 2026.What is the 52 week high and low of Natco Pharma Ltd (NATCOPHARM) share?
The 52-week high of Natco Pharma Ltd (NATCOPHARM) is ₹1341 and the 52-week low is ₹726.80.What is the PE and PB ratio of Natco Pharma Ltd (NATCOPHARM) stock?
The P/E (price-to-earnings) ratio of Natco Pharma Ltd (NATCOPHARM) is 7.99. The P/B (price-to-book) ratio is 1.98.Which sector does Natco Pharma Ltd (NATCOPHARM) belong to?
Natco Pharma Ltd (NATCOPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Natco Pharma Ltd (NATCOPHARM) shares?
You can directly buy Natco Pharma Ltd (NATCOPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Natco Pharma Ltd
NATCOPHARM Share Price
830.801.22% (-10.30)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NATCOPHARM Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NATCOPHARM Performance & Key Metrics
NATCOPHARM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 9.79 | 1.98 | 0.71% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.41 | 5.62 | 0.61% |
40%
Analysts have suggested that investors can buy this stock
from 10 analysts
Price Upside
Earnings Growth
Rev. Growth
NATCOPHARM Company Profile
Natco Pharma Limited is a research and development (R&D)-focused pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
SUNPHARMA
PE Ratio
37.42
37.42
1Y Return
3.45%
3.45%
Buy Reco %
94.44
94.44
TORNTPHARM
PE Ratio
71.25
71.25
1Y Return
29.66%
29.66%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
20.33
20.33
1Y Return
8.44%
8.44%
Buy Reco %
58.06
58.06
DRREDDY
PE Ratio
18.26
18.26
1Y Return
1.66%
1.66%
Buy Reco %
51.61
51.61
LUPIN
PE Ratio
30.57
30.57
1Y Return
3.98%
3.98%
Buy Reco %
72.22
72.22
NATCOPHARM Sentiment Analysis
NATCOPHARM Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
NATCOPHARM Stock Summary · November 2025
In Q2 FY26, the company demonstrated robust financial performance with consolidated revenues of Rs 1,463 crores and strong EBITDA margins of 46.4%, reflecting effective cost management despite rising R&D expenses linked to clinical trials for generics. While the domestic market remains stable, the anticipated launch of Semaglutide is poised to drive future growth, albeit amid intense competition that may pressure profitability. The management's cautious outlook includes a conservative revenue guidance of Rs 750 to 800 crores for the next six months, alongside strategic investments in disruptive opportunities and a planned demerger to unlock shareholder value. Overall, the company is focused on innovation and maintaining a strong pipeline while navigating a challenging competitive landscape.
NATCOPHARM Stock Growth Drivers
NATCOPHARM Stock Growth Drivers
8Strong Financial Performance
The company reported a consolidated total revenue of Rs 1,463 crores for Q2 FY26, an
Successful Product Launches
The recent launch of Risdiplam is expected to strengthen the company's base business. Additionally, the
NATCOPHARM Stock Challenges
NATCOPHARM Stock Challenges
4Declining Sales from Lenalidomide
The company anticipates a significant drop in sales contributions from Lenalidomide, particularly in Q3 and
Increased Competition and Market Uncertainty
The company faces intensified competition that is impacting its market share and revenue expectations. There
NATCOPHARM Forecast
NATCOPHARM Forecasts
Price
Revenue
Earnings
NATCOPHARM Share Price Forecast
NATCOPHARM Share Price Forecast
2026
Current
₹841.10
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹841.10
Baseline
Forecast for Feb 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
NATCOPHARM Company Revenue Forecast
NATCOPHARM Company Revenue Forecast
2025
Current
₹4.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹4.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
NATCOPHARM Stock EPS (Earnings Per Share) Forecast
NATCOPHARM Stock EPS (Earnings Per Share) Forecast
2025
Current
₹105.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹105.26
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
NATCOPHARM
NATCOPHARM
Income
Balance Sheet
Cash Flow
Annual Normal View
NATCOPHARM Income Statement
NATCOPHARM Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,034.10 | 2,225.20 | 2,224.70 | 2,022.40 | 2,155.70 | 2,043.80 | 2,811.70 | 4,126.90 | 4,784.00 | 4,792.00 | ||||||||||
Raw Materials | 617.90 | 436.40 | 388.10 | 456.80 | 559.50 | 577.70 | 651.00 | 673.90 | 702.30 | 2,650.60 | ||||||||||
| Power & Fuel Cost | 50.50 | 56.20 | 59.60 | 62.40 | 61.10 | 76.40 | 81.90 | 88.90 | 93.10 | |||||||||||
| Employee Cost | 243.20 | 325.60 | 355.90 | 375.00 | 414.90 | 444.80 | 486.70 | 525.00 | 594.50 | |||||||||||
| Selling & Administrative Expenses | 299.60 | 304.50 | 351.10 | 311.60 | 300.90 | 367.70 | 388.80 | 604.00 | 548.00 | |||||||||||
| Operating & Other expenses | 125.60 | 133.70 | 145.00 | 126.60 | 109.50 | 214.70 | 163.10 | 355.60 | 295.60 | |||||||||||
EBITDA | 697.30 | 968.80 | 925.00 | 690.00 | 709.80 | 362.50 | 1,040.20 | 1,879.50 | 2,550.50 | 2,141.40 | ||||||||||
| Depreciation/Amortization | 54.40 | 66.20 | 81.00 | 99.80 | 116.90 | 142.60 | 163.80 | 186.80 | 235.20 | 255.30 | ||||||||||
| PBIT | 642.90 | 902.60 | 844.00 | 590.20 | 592.90 | 219.90 | 876.40 | 1,692.70 | 2,315.30 | 1,886.10 | ||||||||||
| Interest & Other Items | 18.50 | 15.40 | 19.30 | 21.50 | 13.30 | 17.70 | 14.50 | 19.20 | 23.90 | 30.90 | ||||||||||
| PBT | 624.40 | 887.20 | 824.70 | 568.70 | 579.60 | 202.20 | 861.90 | 1,673.50 | 2,291.40 | 1,855.20 | ||||||||||
| Taxes & Other Items | 138.40 | 191.00 | 180.30 | 107.90 | 138.70 | 32.20 | 146.60 | 285.20 | 406.00 | 316.50 | ||||||||||
| Net Income | 486.00 | 696.20 | 644.40 | 460.80 | 440.90 | 170.00 | 715.30 | 1,388.30 | 1,885.40 | 1,538.70 | ||||||||||
| EPS | 27.89 | 38.81 | 35.09 | 25.26 | 24.20 | 9.32 | 39.22 | 76.79 | 105.26 | 85.91 | ||||||||||
| DPS | 6.75 | 8.25 | 6.25 | 6.75 | 5.25 | 4.50 | 5.50 | 9.50 | 6.00 | 5.00 | ||||||||||
| Payout ratio | 0.24 | 0.21 | 0.18 | 0.27 | 0.22 | 0.48 | 0.14 | 0.12 | 0.06 | 0.06 |
NATCOPHARM Company Updates
FY 2026FY 2026
Investor Presentation
Aug 12PDF
Jul 23PDF
Jul 23PDF
NATCOPHARM Stock Peers
NATCOPHARM Past Performance & Peer Comparison
NATCOPHARM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Natco Pharma Ltd | 7.99 | 1.98 | 0.71% |
| Sun Pharmaceutical Industries Ltd | 37.42 | 5.64 | 0.94% |
| Torrent Pharmaceuticals Ltd | 71.25 | 17.94 | 0.80% |
| Cipla Ltd | 20.33 | 3.43 | 1.21% |
NATCOPHARM Stock Price Comparison
Compare NATCOPHARM with any stock or ETFCompare NATCOPHARM with any stock or ETF
NATCOPHARM
NATCOPHARM Holdings
NATCOPHARM Shareholdings
NATCOPHARM Promoter Holdings Trend
NATCOPHARM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NATCOPHARM Institutional Holdings Trend
NATCOPHARM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Increased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has increased by 1.07%
NATCOPHARM Shareholding Pattern
NATCOPHARM Shareholding Pattern
NATCOPHARM Shareholding History
NATCOPHARM Shareholding History
Foreign Institutions
Mutual Funds Invested in NATCOPHARM
Mutual Funds Invested in NATCOPHARM
No mutual funds holding trends are available
Top 5 Mutual Funds holding Natco Pharma Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0456% | Percentage of the fund’s portfolio invested in the stock 0.28% | Change in the portfolio weight of the stock over the last 3 months 0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/135 (+47) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0210% | Percentage of the fund’s portfolio invested in the stock 0.69% | Change in the portfolio weight of the stock over the last 3 months 0.69% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 52/81 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0156% | Percentage of the fund’s portfolio invested in the stock 1.51% | Change in the portfolio weight of the stock over the last 3 months 0.15% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/32 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing NATCOPHARM stock
smallcases containing NATCOPHARM stock
Looks like this stock is not in any smallcase yet.
NATCOPHARM Events
NATCOPHARM Events
NATCOPHARM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.71%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.13 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NATCOPHARM Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.71%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.13 every year
NATCOPHARM Upcoming Dividends
NATCOPHARM Upcoming Dividends
No upcoming dividends are available
NATCOPHARM Past Dividends
NATCOPHARM Past Dividends
Cash Dividend
Ex DateEx DateNov 20, 2025
Interim 2
Interim 2 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Nov 20, 2025
Cash Dividend
Ex DateEx DateAug 19, 2025
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 19, 2025
Cash Dividend
Ex DateEx DateFeb 18, 2025
Interim 3
Interim 3 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Feb 18, 2025
Cash Dividend
Ex DateEx DateNov 27, 2024
Interim 2
Interim 2 | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Nov 27, 2024
Cash Dividend
Ex DateEx DateAug 23, 2024
Interim
Interim | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 23, 2024
NATCOPHARM Stock News & Opinions
NATCOPHARM Stock News & Opinions
Articles & Videos
Corporate
NATCO Pharma receives USFDA tentative approval for Erdafitinib tablets
NATCO Pharma received tentative approval from the USFDA for Erdafitinib, 3 mg, 4mg, and 5 mg, a generic version of Balversa' by Janssen Biotech Inc. NATCO's Erdafitinib is indicated for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma harbouring susceptible FGFR3 genetic alterations who have disease progression during at least 1 line of prior therapy. Erdafitinib tablets had estimated sales of approximately USD 60 million in the U.S. for 12 months ending Sep'25 as per industry sales data.Powered by Capital Market - Live
1 day agoCapital Market - Live
Corporate
NATCO Pharma Asia acquires 49% stake in PT NATCO Lotus Farma
NATCO Pharma Asia, a wholly-owned subsidiary (WOS) of Natco Pharma (NATCO) incorporated in Singapore, has acquired 49% of shareholding in PT NATCO Lotus Farma from PT Lotus Farma Indonesia. NATCO already owns 51% of PT NATCO Lotus Farma. Post this acquisition, NATCO along with its WOS wholly-owns 100% of PT NATCO Lotus Farma.Powered by Capital Market - Live
6 days agoCapital Market - Live
Corporate
Natco Pharma to hold board meeting
Natco Pharma will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
1 week agoCapital Market - Live
Corporate
Natco Pharma announces change in senior management
Natco Pharma has appointed Amit Parekh as Executive Vice President - Finance and Accounts of the Company with effect from 2nd December 2025 and as part of the Company's structured succession planning; subject to necessary approvals; Amit Parekh will succeed S.V.V.N. Appa Rao, Chief Financial Officer of the Company at the Board meeting to be held in the month of February 2026. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Natco Pharma receives affirmation in credit ratings from ICRA
Natco Pharma announced that ICRA has reaffirmed/ assigned the rating ICRA AA; Stable/ ICRA A1+ for various debt facilities of the company. Powered by Capital Market - Live
2 months agoCapital Market - Live
Spotlight
Natco Pharma slides after receiving seven USFDA observations for Chennai API plant
According to the company's exchange filing, the inspection was carried out between 17 November and 21 November 2025. Natco stated that the observations are procedural in nature and expressed confidence in addressing them comprehensively. The company added that it remains committed to maintaining cGMP compliance and ensuring the supply of high-quality products to customers and patients worldwide. NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company's consolidated net profit fell 23.5% to Rs 518.40 crore in Q2 FY26, compared with Rs 677.30 crore in Q2 FY25. Revenue from operations declined marginally to Rs 1,363 crore in Q2 FY26, compared with Rs 1,371.10 crore in Q2 FY25. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Natco Pharma concludes USFDA inspection of its API unit in Chennai
Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025. On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively. Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Natco Pharma fixes record date for interim dividend
Natco Pharma has fixed 20 November 2025 as record date for payment of interim dividend of Rs 1.50 per share. The dividend will be paid from 28 November 2025. Powered by Capital Market - Live
2 months agoCapital Market - Live
Earnings
Natco Pharma consolidated net profit declines 23.46% in the September 2025 quarter
Net profit of Natco Pharma declined 23.46% to Rs 518.40 crore in the quarter ended September 2025 as against Rs 677.30 crore during the previous quarter ended September 2024. Sales declined 0.59% to Rs 1363.00 crore in the quarter ended September 2025 as against Rs 1371.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1363.001371.10 -1 OPM %42.4958.66 - PBDT666.10864.00 -23 PBT613.70818.20 -25 NP518.40677.30 -23 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Board of Natco Pharma recommends interim dividend
Natco Pharma announced that the Board of Directors of the Company at its meeting held on 14 November 2025, inter alia, have recommended the interim dividend of Rs 1.5 per equity Share (i.e. 75%) , subject to the approval of the shareholders.Powered by Capital Market - Live
2 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 18.79%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.8% to 1.13%
Over the last 5 years, net income has grown at a yearly rate of 32.55%, vs industry avg of 20.02%